Apiam Animal Health Limited (ASX:AHX) H1 FY23 Results Release and Investor Presentation
Apiam Animal Health Limited (ASX:AHX) is pleased to release its full year results for the 6-months to 31 December 2022 (H1 FY23).
Companies in the News
Biotech
Apiam Animal Health Limited (ASX:AHX) H1 FY23 Reporting Date and Investor Webinar Notification
Apiam Animal Health Limited (ASX:AHX) will release its financial results for the six months ended 31 December 2022 on Friday 24 February 2023.
VIDEO: Apiam Animal Health Ltd (ASX:AHX) Interview with Dr. Chris Richards on Recent Acquisitions
Apiam Animal Health Ltd (ASX:AHX) MD Dr. Chris Richards speaks with ABN Newswire on the recent acquisitions the company has made in the mixed animal veterinary industry.
VGI Health Technology Limited (NSX:VTL) Quarterly Update
The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 31 December 2022.
Apiam Animal Health Limited (ASX:AHX) Strategic NSW Acquisitions Into Two New High-Growth Regions
Apiam Animal Health Limited (ASX:AHX) is pleased to announce the acquisition of two mixed animal veterinary businesses in strategic NSW regions (the Acquisitions), for total consideration of $11.2 million.
Proteomics International Laboratories Limited (ASX:PIQ) Announce AMA Approval of PromarkerD Test for Diabetic Kidney Disease
American Medical Association approves CPT PLA code for PromarkerD predictive test for diabetic kidney disease
VGI Health Technology Limited (NSX:VTL) Update on Sale of Invictus BioPharma
On 5 April 2022, the Directors of VGI Health Technology Limited (NSX:VTL) announced the sale of its wholly owned subsidiary, Invictus BioPharma Pty Ltd to Invictus BioPharma Holdings Ltd (IVBHL) (the Transaction).
◂Previous Page
Biotech Next Page▸
Banking & Finance
- NSX Limited (ASX:NSX) Company Update
- ASIC vs iSignthis Ltd and Nickolas John Karantzis
- NSX Limited (ASX:NSX) Appointment of Managing Director and CEO - Max Cunningham
Social Media
